Alertgy A revolutionary approach to diabetes monitoring

Diabetes is a major chronic disease across the world. Around 20% of the world population aged above 65 is affected by this disease. The International Diabetes Federation reports that by 2019, about 463 million adults between 20-79 years of age had diabetes.

It is estimated that by 2045, the figure will rise to 700 million worldwide. According to the Centre for Disease Control, 10.5% of the US population suffers from diabetes. The conventional approach to measuring blood glucose levels uses invasive techniques to draw blood from the patients. Advanced stages of diabetes require continuous monitoring. Hence, using traditional methods is not without pain and can become difficult in older people. Marc Rippen, CEO of Alertgy, propelled the idea of a smart glucose monitor as an alternative to traditional systems. This revolutionary device will be the first-of-its-kind wearable glucose monitor.

The First Non-invasive Glucose Monitor

Alertgy has pioneered the noninvasive continuous blood glucose monitoring technology. The present continuous glucose monitors require electrodes to be placed under the skin. However, Alertgy’s DeepGluco wearable device uses the patented radiofrequency sensor to monitor blood glucose. This makes the technology noninvasive, with the ability to measure the glucose level in real-time up to three times per minute. Moreover, it is hypo-allergic, waterproof, and can be worn round the clock.
DeepGluco uses Alertgy’s proprietary algorithm to provide life-saving alerts to users and health care practitioners. The wearable continuous glucose monitor also averts the side effects of patches, needles, and implants used in traditional CGMs. Currently, the device is in its prototype stage. The final
DeepGluco device will be in the form of a smartwatch. With the help of inputs from active patients, the prototype will be subjected to various tests and improvements. It will be available to consumers upon FDA approval, possibly by 2022.

A Vision for Social Well-being

Marc Rippen envisions improving the well-being of diabetics across the globe. Moreover, there are numerous people on the verge of getting diabetes. Timely diagnosis can help prevent them from the early onset of diabetes. This necessitates the need to provide a universal, cost-effective solution that will be a breakthrough in treating chronic diseases like diabetes. Advancements in cloud-based IoT sensor systems, the application of AI 10, and improvements in wearables have a profound impact on the medical and diagnostic industry. Rippen, utilizing his 40 years of experience, seeks to apply cutting-edge sensor technology to measure blood glucose levels in the form of a wearable device. Moreover, Alertgy is endeavoring to make the device affordable to everyone.

David Karp

A technology engineer, Marc Rippen has worked in multiple fortune 500 companies. In his experience of more than 30 years, Rippen has learned that success requires hard work, conviction, personal experience, and resilience. He leveraged his personal experience with diabetes for devising this innovative product. Alertgy’s best efforts to fulfill its goal are reflected by the numerous industry awards that the company has won during its journey. The recognitions include the first prize at the ‘Nasa Itech ignite’ and $15,000 prize at the ‘FAU pitch deck competition.’ Rippen has always believed that assembling an ‘A-team’ is the key to success. He has focused on finding professionals who can help make Alertgy happen. The company’s executive team comprises the CFO, Rob Strandberg; Director and Chief Business Development Officer, Alex Radetich; Chief Technology Officer John W. Hodges Jr.; Chief Manufacturing Officer, Craig R. Nelson; Chief Medical Officer Dr. Helga Rippen. These creative, brilliant, out-of-the-box thinkers help Rippen with his mission to provide effective and care-free solutions to people with diabetes.

Future Outlook of the Company

Alertgy has been associated with diabetes associations and patient advocacy groups, providing goodwill, education, and testing. This innovative technology can positively affect more than 90% of diabetes patients worldwide. The DeepGluco CGM developed by Rippen and his team will provide an effortless means to measure blood glucose levels. The company will pursue an alert and surveillance approval from the FDA in the future.
To date, Alertgy has raised $3.3M in seed and bridge funding under the leadership of Rippen. He is focused on expanding this further to a $10M Series A round. There is sufficient published research indicating that Alertgy’s innovative technology can track other metabolites and cellular markers within the body. This has created a potential for the technology to diagnose different diseases.
Continuing to contribute to the cure, Marc Rippen hopes that his tech will be life-changing for millions of people suffering from diabetes. This unique solution by Alertgy exemplifies the potential of technology in helping humankind. By leveraging technology’s unlimited potential, Marc Rippen has set his sights on establishing Alertgy as a premium leader in diagnostic technology.